Cargando…

Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation

BACKGROUND: Patients with mechanical heart valves (MHV) require warfarin to prevent thromboembolism. Although dabigatran was as effective as warfarin for stroke prevention in atrial fibrillation when compared with warfarin in patients with MHV, the study was stopped early because of more strokes and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaffer, Iqbal H, Stafford, Alan R, Fredenburgh, James C, Whitlock, Richard P, Chan, Noel C, Weitz, Jeffrey I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599481/ https://www.ncbi.nlm.nih.gov/pubmed/26304938 http://dx.doi.org/10.1161/JAHA.115.002322

Ejemplares similares

Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function
por: Yeh, Calvin H., et al.
Publicado: (2016)

Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice
por: Pingel, Simon, et al.
Publicado: (2014)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Uninterrupted dabigatran is safer than warfarin in patients undergoing ablation for atrial fibrillation
por: Spartalis, Michael, et al.
Publicado: (2017)

Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
por: Xu, Xiaoping, et al.
Publicado: (2019)

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017)

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: Protocol
por: Duraes, Andre Rodrigues, et al.
Publicado: (2014)

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
por: Reynolds, Shannon L., et al.
Publicado: (2017)

Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)
Publicado: (2010)

Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran
por: Grossmann, Klaus
Publicado: (2021)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
por: Durães, André Rodrigues, et al.
Publicado: (2016)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin – a model-based study
por: Edrich, Thomas, et al.
Publicado: (2015)

Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
por: Andrade, Marcus Vinicius Santos, et al.
Publicado: (2018)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Dabigatran in the Treatment of Warfarin-Induced Skin Necrosis: A New Hope
por: Bakoyiannis, Christos, et al.
Publicado: (2016)

Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review
por: Ganji, Reza, et al.
Publicado: (2016)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
por: Avezum, Alvaro, et al.
Publicado: (2018)

Data regarding the effects of thrombin and dabigatran-inhibited thrombin on protease-activated receptor 1 and activation of human atrial fibroblasts
por: Altieri, Paola, et al.
Publicado: (2018)

Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway
por: Ewees, Mohamed Gamal El-Din, et al.
Publicado: (2021)

Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin
por: Moeckel, Gilbert W., et al.
Publicado: (2013)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function
por: Fusaro, Maria, et al.
Publicado: (2015)

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
por: Liu, Zhiyan, et al.
Publicado: (2022)

Dabigatran reduces thrombin-induced neuroinflammation and AD markers in vitro: Therapeutic relevance for Alzheimer's disease
por: Bihaqi, Syed Waseem, et al.
Publicado: (2021)

Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
por: Lauffenburger, Julie C., et al.
Publicado: (2015)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ppm80sdrtakliht3klsbe86kj4